. 2018 Jul 23;3(5):e000346. doi: 10.1136/esmoopen-2018-000346

Table 4.

Overall survival according to the CI-IR status in patients with HNSCC (locally advanced disease and recurrent or metastatic disease)

		Overall survival median, (95% CI)	Log rank test
Patients with locally advanced disease HNSCC treated by cetuximab potentiated chemoradiation	CI-IR, n=6	42.9 (5.3 to NA) months	0.51
	No CI-IR, n=180	22.6 (16.0 to 46.0) months	0.51
Patients with recurrent or metastatic disease HNSCC treated by cetuximab-based systemic chemotherapy	CI-IR, n=18	6.5 (5.4 to NA) months	0.17
	No CI-IR, n=223	12.7 (11.1 to 16.2) months	0.17

CI-IR, cetuximab-induced infusion reaction; HNSCC, head and neck squamous cell carcinoma.